Proteinaceous cysteine protease inhibitors

Cellular and Molecular Life Sciences

Volumn 62, Issue 6, 2005, Pages 653-669

  Dubin, G ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Inhibitor; Peptidase; Protease; Proteinase

Indexed keywords

CALPASTATIN; CHAGASIN; CLITOCYPIN; CYSTATIN; CYSTATIN C; CYSTEINE PROTEINASE INHIBITOR; CYTOKINE RESPONSE MODIFIER A; ENZYME INHIBITOR; EQUISTATIN; FUNGAL PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; KININOGEN; LEGUMAIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P35; SAXIPHILIN; SOMATOMEDIN BINDING PROTEIN; STAPHOSTATIN; STEFIN A; STEFIN B; THYROGLOBULIN; UNCLASSIFIED DRUG;

CHAGAS DISEASE; GENE MAPPING; GENE MUTATION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

AMPHIBIAN PROTEINS; ANIMALS; BACTERIAL PROTEINS; CALCIUM-BINDING PROTEINS; CARRIER PROTEINS; CYSTATINS; CYSTEINE PROTEINASE INHIBITORS; FUNGAL PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; KININOGENS; PROTEINS; PROTOZOAN PROTEINS; SERPINS; VIRAL PROTEINS;

EID: 17044379501     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4445-9     Document Type: Review

References (151)

1. Rawlings N. D., Tolle D. P. and Barrett A. J. (2004) Evolutionary families of peptidase inhibitors. Biochem. J. 378: 705-716
2. Rzychon M., Chmiel D. and Stec-Niemczyk J. (2004) Modes of inhibition of cystein proteases. Acta Biochim. Pol. 51: 861-873
3. Stubbs M. T., Laber B., Bode W., Huber R., Jerala R., Lenarcic B. et al. (1990) The refined 2.4 Å X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO 9: 1939-1947
4. Abrahamson M., Alvarez-Fernandez M. and Nathanson C.-M. (2003) Cystatins. Biochem. Soc. Symp. 70: 179-199
5. Martin J. R., Craven C. J., Jerala R., Kroon-Zitko L., Zerovnik E., Turk V. et al. (1995) The three-dimensional solution structure of human stefin A. J. Mol. Biol. 246: 331-343
6. Nemes Z. and Steinert P. M. (1999) Bricks and mortar of the epidermal barrier. Exp. Mol. Med. 31: 5-19
7. Zettergren J. G., Peterson L. L. and Wuepper K. D. (1984) Keratolinin: the soluble substrate of epidermal transglutaminase from human and bovine tissue. Proc. Natl. Acad. Sci. USA 81: 238-242
8. Takahashi M., Tezuka T. and Katunuma N. (1992) Phosphorylated cystatin α is a natural substrate of epidermal transglutaminase for formation of skin cornified envelope. FEBS Lett. 308: 79-82
9. Steinert P. M. and Marekov L. N. (1997) Direct evidence that involucrin is a major early isopeptide cross-linked component of the kerationcyte cornified cell envelope. J. Biol. Chem. 272: 2021-2030
10. Takahashi M., Tezuka T. and Katunuma N. (1994) Inhibition of growth and cysteine proteinase activity of Staphylococcus aureus V8 by phosphorylated cystatin α in skin cornified envelope. FEBS Lett. 355: 275-278
11. Pennacchio L. A., Bouley D. M., Higgins K. M., Scott M. P., Noebels J. L. and Myers R. M. (1998) Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat. Genet. 20: 251-258
12. Shannon P., Pennacchio L. A., Houseweart M. K., Minassian B. A. and Myers R.M. (2002) Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. J. Neuropathol. Exp. Neurol. 61: 1085-1091
13. Lalioti M. D., Antonarakis S. E. and Scott H. S. (2003) The epilepsy, the protease inhibitor and the dodecamer: progressive myoclonus epilepsy, cystatin b and a 12-mer repeat expansion. Cytogenet. Genome Res. 100: 213-223
14. Grubb A. and Löfberg H. (1982) Human γ-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc. Natl. Acad. Sci. USA 79: 3024-3027
15. Turk B., Turk D. and Salvesen G. S. (2002) Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. 8: 1623-1637
16. Hull C.-G., Håkansson K., Nathanson C.-M., Thorgeirsson U. P., Jonsson N., Grubb A. et al. (1999) Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. J. Clin. Pathol. 52: 332-340
17. Palsdottir A., Abrahamson M., Thorsteinsson L., Arnason A., Olafsson I., Grubb A. et al. (1988) Mutation in cystatin C gene causes hereditary brain hemorrhage. Lancet 2: 603-604
18. Abrahamson M., Jonsdottir S., Olafsson I., Jensson O. and Grubb A. (1992) Hereditary cystatin C amyloid angiopathy: identification of the disease-causing mutation and specific diagnosis by polymerase chain reaction based analysis. Hum. Genet. 89: 377-380
19. Abrahamson M. and Grubb A. (1994) Increased body temperature accelerates aggregation of the Leu-68→ Gln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. Proc. Natl. Acad. Sci. USA 91: 1416-1420
20. Shi G.-P., Sukhova G. K., Grubb A., Ducharme A., Rhode L. H., Lee R. T. et al. (1999) Cystatin C deficiency in human arteriosclerosis and aortic aneurysms. J. Clin. Invest. 104: 1191-1197
21. Björck L., Grubb A. and Kjellen L. (1990) Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J. Virol. 64: 941-943
22. Collins A. R. and Grubb A. (1991) Inhibitory effects of recombinant human cystatin C on human coronaviruses. Antimicrob. Agents Chemother. 35: 2444-2446
23. Freije J. P., Balbin M., Abrahamson M., Velasco G., Dalboge H., Grubb A. et al. (1993) Human cystatin D. cDNA cloning, characterization of the Escherichia coli expressed inhibitor, and identification of the native protein in saliva. J. Biol. Chem. 268: 15737-15744
24. Collins A. R. and Grubb A. (1998) Cystatin D, a natural salivary cysteine protease inhibitor, inhibits coronavirus replication at its physiologic concentration. Oral Microbiol. Immunol. 13: 59-61
25. Shaw P. A. and Yu W. H. (2001) Sympathetic and parasympathetic regulation of cystatin S gene expression. Life Sci. 70: 301-313
26. Alves J. B., Alves M. S. and Naito Y. (1994) Induction of synthesis of the rat cystatin S protein by the submandibular gland during the acute phase of experimental Chagas disease. Mem. Inst. Oswaldo Cruz 89: 81-85
27. Blankenvoorde M. F., Henskens Y. M., van't Hof W., Veerman E. C. and Nieuw Amerongen A. V. (1996) Inhibition of the growth and cysteine proteinase activity of Porphyromonas gingivalis by human salivary cystatin S and chicken cystatin. Biol. Chem. 377: 847-850
28. Naito Y., Suzuki I. and Hasegawa S. (1992) Induction of cystatin S in rat submandibular glands by papain. Comp. Biochem. Physiol. 102: 861-865
29. Zeeuwen P. L., van Vlijmen-Willems I. M., Jansen B. J., Sotiropoulou G., Curfs J. H., Meis J. F. et al. (2001) Cystatin M/E expression is restricted to differentiated epidermal keratinocytes and sweat glands: a new skin-specific proteinase inhibitor that is a target for cross-linking by transglutaminases. J. Invest. Dermatol. 116: 693-701
30. Sotiropoulou G., Anisowicz A. and Sager R. (1997) Identification, cloning and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J. Biol. Chem. 272: 903-910
31. Shridhar R., Zhang J., Song J., Booth B. A., Kevil G. C., Sotiropoulou G. et al. (2004) Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 23: 2206-2215
32. Vigneswaran N., Wu J. and Zacharias W. (2003) Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumor to metastasis. Oral. Oncol. 39: 559-568
33. Zeeuwen P. L., van Vlijmen-Willems I. M., Hendriks W., Merkx G. F. and Schalkwijk J. (2002) A null mutation in the cystatin M/E gene of ichq mice causes juvenile lethality and defects in epidermal cornification. Hum. Mol. Genet. 11: 2867-2875
34. Zeeuwen P. L., Dale B. A., de Jongh G. J., van Vlijmen-Willems I. M., Fleckman P., Kimball J. R. et al. (2003) The human cystatin M/E gene (CST6): exclusion candidate gene for harlequin ichthyosis. J. Invest. Dermatol. 121: 65-68
35. Zeeuwen P. L., van Vlijmen-Willems I. M., Olthuis D., Johansen H. T., Hitomi K., Hara-Nishimura I. et al. (2004) Evidence that unrestricted legumain activity is involved in disturbed epidermal cornification in cystatin M/E deficient mice. Hum. Mol. Genet. 13: 1069-1079
36. Halfon S., Ford J., Foster J., Dowling L., Lucian L., Sterling M. et al. (1998) Leukocystatin, a new class II cystatin expressed selectively by haematopoietic cells. J. Biol. Chem. 273: 16400-16408
37. Ni J., Fernandez M. A., Danielsson L., Chillakuru R. A., Zhang J., Grubb A. et al. (1998) Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor. J. Biol. Chem. 273: 24797-24804
38. Journet A., Chapel A., Kieffer S., Roux F. and Garin J. (2002) Proteomic analysis of human lysosomes: application to monocytic and breast cancer cells. Proteomics 2: 1026-1040
39. Nathanson C.-M., Wassélius J., Wallin H. and Abrahamson M. (2002) Regulated expression and intracellular localization of cystatin F in human U937 cells. Eur. J. Biochem. 269: 5502-5511
40. Cappello F., Gatti E., Camossetto V., David A., Lelouard H. and Pierre P. (2004) Cystatin F is secreted but artificial modification of its C-terminus can induce its endocytic targeting. Exp. Cell Res. 297: 607-618
41. Morita M., Yoshiuchi N., Arakawa H. and Nishimura S. (1999) CMAP: a novel cystatin-like gene involved in liver metastasis. Cancer Res. 59: 151-158
42. Salvesen G., Parkes C., Abrahamson M., Grubb A. and Barrett A. J. (1986) Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem. J. 234: 429-434
43. Schmaier A. H. (2002) The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J. Clin. Invest. 109: 1007-1009
44. Ueno A. and Oh-ishi S. (2003) Roles for the kallikrein-kinin system in inflammatory exudation and pain: lessons from studies on kininogen-deficient rats. J. Pharmacol. Sci. 93: 1-20
45. Saito H., Ratnoff O. D., Waldmann R. and Abraham J. P. (1975) Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability (PF/dil). J. Clin. Invest. 55: 1082-1089
46. Colman R. W., Bagdasarian A., Talamo R. C., Scott C. F., Seavey M., Guimaraes J. A. et al. (1975) Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J. Clin. Invest. 56: 1650-1662
47. Alvarez-Fernandez M., Barrett A. J., Gerhartz B., Dando P. M., Ni J. and Abrahamson M. (1999) Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J. Biol. Chem. 274: 19195-19203
48. Monteiro A. C. S., Abrahamson M., Lima A. P. C. A., Vannier-Santos M. A. and Scharfstein J. (2001) Identification, characterization and localization of chagasin, a tight-binding cysteine protease inhibitor in Trypanosoma cruzi. J. Cell Sci. 114: 3933-3942
49. Rigden D. J., Mosolov V. V. and Galperin M. Y. (2002) Sequence conservation in the chagasin family suggests a common trend in cysteine proteinase binding by unrelated protein inhibitors. Prot. Sci. 11: 1971-1977
50. Sanderson S. J., Westrop G. D., Scharfstein J., Mottram J. C. and Coombs G. H. (2003) Functional conservation of a natural cysteine peptidase inhibitor in protozoan and bacterial pathogens. FEBS Lett. 542: 12-16
51. Caffrey C. R., Scory S. and Steverding D. (2000) Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets 1:155-162
52. Brzin J., Rogelj B., Popovič T., Strukelj B. and Ritonja A. (2000) Clitocypin, a new type of cysteine proteinase inhibitor from fruit bodies of mushroom Clitocybe nebularis. J. Biol.Chem. 275: 20104-20109
53. Kidrič M., Fabion H., Brzin J., Popovič T. and Pain R. H. (2002) Folding, stability and secondary structure of a new dimeric cysteine proteinase inhibitor. Biochem. Biophys. Res. Comm. 297: 962-967
54. Rzychon M., Sabat A., Kosowska K., Potempa J. andDubin A. (2003) Staphostatins: an expanding new group of proteinase inhibitors with a unique specificity for the regulation of staphopains, Staphylococcus spp. cysteine proteinases. Mol. Microbiol. 49: 1051-1066
55. Dubin G., Stec-Niemczyk J., Dylag T., Silberring J., Dubin A. and Potempa, J. (2004) Characterisation of a highly specific, endogenous inhibitor of cysteine protease from Staphylococcus epidermidis, a new member of the staphostatin family. Biol. Chem. 385: 543-546
56. Dubin G., Krajewski M., Popowicz G., Stec-Niemczyk J., Bochtler M., Potempa J. et al. (2003). A novel class of cysteine protease inhibitors: solution structure of staphostatin A from Staphylococcus aureus. Biochemistry 42: 13449-13456
57. Filipek R., Rzychon M., Oleksy A., Gruca M., Dubin A., Potempa J. et al. (2003) The staphostatin-staphopain complex: a forward binding inhibitor in complex with its target cysteine protease. J. Biol. Chem. 278: 40959-40966
58. Rzychon M., Filipek R., Sabat A., Kosowska K., Dubin A., Potempa J. et al. (2003) Staphostatins resemble lipocalins, not cystatins in fold. Protein Sci. 12: 2252-2256
59. Wladyka B., Puzia K. and Dubin A. (2005) Efficient coexpression of a recombinant staphopain A and its inhibitor staphostatin A in Escherichia coli. Biochem. J. 385: 181-187
60. Strobl S., Fernandez-Catalan C., Braun M., Huber R., Masumoto H., Nakagawa K. et al. (2000) The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium. Proc. Natl. Acad. Sci. USA 97: 588-592
61. 2+ channels in guinea pig cardiac myocytes. Biochem. Biophys. Res. Comm. 279: 756-761
62. Todd B., Moore D., Deivanayagam C. C. S., Lin G., Chattopadhyay D., Maki M. et al. (2003) A structural model for the inhibition of calpain by calpastatin: crystal structures of the native domain VI of calpain and its complexes with calpastatin peptide and a small molecule inhibitor. J. Mol. Biol. 328: 131-146
63. Goll D. E., Thompson V. F., Li H., Wei W. and Cong J. (2003) The calpain system. Physiol. Rev. 83: 731-801
64. Averna M., De Tullio R., Passalacqua M., Salamino F., Pontremoli S. and Melloni E. (2001) Changes in intracellular calpastatin localization are mediated by reversible phosphorylation. Biochem. J. 354: 25-30
65. Salamino F., Averna M., Tedesco I., De Tullio R., Melloni E. and Pontremoli S. (1997) Modulation of rat brain calpastatin efficiency by post-translational modifications. FEBS Lett. 412: 433-438
66. Arthur J. S., Elce J. S., Hegadoni C., Williams K. and Greer P. A. (2000). Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol. Cell. Biol. 20: 4474-4481
67. Zimmerman U. J. P., Boring L., Pak J. H., Mukerjee N. and Wang K. K. (2000) The calpain small subunit is essential: its inactivation results in embryonic lethality. IUBMB Life 50: 63-68
68. Azam M., Andrabi S. S., Sahr K. E., Kamath L., Kuliopulos A. and Chishti A. H. (2001) Disruption of the mouse μ-calpain gene reveals an essential role in platelet function. Mol. Cell. Biol. 21: 2213-2220
69. Barnoy S. and Kosower N. S. (2003) Caspase-1-induced calpastatin degradation in myoblast differentiation and fusion: cross-talk between the caspase and calpain system. FEBS Lett. 546: 213-217
70. Barnoy S., Supino-Rosin L. and Kosower N. S. (2000) Regulation of calpain and calpastatin in differentiating myoblasts: mRNA levels, protein synthesis and stability. Biochem. J. 351: 413-420
71. Rojas F. J., Brush M. and Moretti-Rojas I. (1999) Calpain-calpastatin: a novel, complete calcium-dependent protease system in human spermatozoa. Mol. Hum. Reprod. 5: 520-526
72. Potter D. A., Tirnauer J. S., Janssen R., Croall D. E., Hughes C. N., Fiacco K. A. et al. (1998) Calpain regulates actin remodelling during cell spreading. J. Cell. Biol. 141: 647-662
73. Dourdin N., Bhatt A. K., Dutt P., Greer P. A., Arthur J. S. C., Elce J. S. et al. (2001) Reduced cell migration and disruption of the actin cytoskeleton in calpain-deficient embryonic fibroblasts. J. Biol.Chem. 276: 48382-48388
74. Squier M. K., Sehnert A. J., Sellins K. S., Malkinson A. M., Takano E. and Cohen J. J. (1999) Calpain and calpastatin regulate neutrophil apoptosis. J. Cell. Physiol. 178: 311-319
75. Porn-Ares M. I., Samali A. and Orrenius S. (1998) Cleavage of the calpain inhibitor, calpastatin, during apoptosis. Cell Death Differ. 5: 1028-1033
76. Muller D., Molinari I., Soldati L. and Bianchi G. (1995) A genetic deficiency in calpastatin and isovalerylcarnitine treatment is associated with enhanced hippocampal long term potentiation. Synapse 19: 37-45
77. Saito Y., Saido T. C., Sano K. and Kawashima S. (1994) The calpain-calpastatin system is regulated differentially during human neuroblastoma cell differentiation to Schwannian and neuronal cells. FEBS Lett. 353: 327-331
78. Carragher N. O. and Frame M. C. (2002) Calpain: a role in cell transformation and migration. Int. J. Biochem. Cell Biol. 34: 1539-1543
79. Perrin B. J. and Huttenlocher A. (2002) Calpain. Int. J. Biochem. Cell Biol. 34:722-725
80. Chen F., Demeras L. M., Vallyathan V., Lu Y., Castranova V. and Shi X. (2000) Impariment of NF-κB activation and modulation of gene expression by calpastatin. Am. J. Physiol. Cell Physiol. 279: 709-716
81. Huang Y. and Wang K. K. (2001) The calpain family and human disease. Trends Mol. Med. 7: 355-362
82. Fukui I., Tanaka K. and Murachi T. (1989) Extracellular appearance of calpain and calpastatin in the synovial fluid of the knee joint. Biochem. Biophys. Res. Comm. 162: 559-566
83. Mimori T., Suganuma K., Tanami Y., Nojima T., Matsumura M., Fujii T. et al. (1995) Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc. Natl. Acad. Sci. USA 92: 7267-7271
84. Lackner K. J., Schlosser U., Lang B. and G. Schmitz (1988) Autoantibodies against human calpastatin in rheumatoid arthritis: epitope mapping and analysis of patient sera. Brit. J. Rheumatol. 37: 1164-1171
85. Newcomb J. K., Pike B. R., Zhao X., Banik N. L. and Hayes R. L. (1999) Altered calpastatin protein levels following traumatic brain injury in rat. J. Neurotrauma 16: 1-11
86. Pontremoli S., Salamino F., Sparatore B., De Tullio R., Pontremoli R. and Melloni E. (1988) Characterization of calpastatin defect in erythrocytes from patients with essential hypertension. Biochem. Biophys. Res. Commum. 157: 867-874
87. Soldati L., Molinari I., Salardi S., Barber B. R., Ruggiero M., Serra F. et al. (1991) Calpastatin level in spontaneously hypertensive rats. Biochem. Biophys. Res. Commum. 175: 486-491
88. Soldati L. P., Barber B. R., Salardi S., Molinari I. and Bianchi G. (1995) A new rat model for studying the calpain-calpastatin system. Lab. Anim. 29: 420-426
89. Koide S. S., Wang L. and Kamada M. (2000) Antisperm antibodies associated with infertility: properties and encoding genes of target antigens. P. S. E. B. M. 224: 124-132
90. Nakayama J., Yoshizawa T., Yamamoto N. and Arinami T. (2002) Mutation analysis of the calpastatin gene (CAST) in patients with Alzheimer's disease. Neurosci. Lett. 320: 77-80
91. Mouatt-Prigent A., Karlsson J. O., Yelnik J., Agid Y. and Hirsch E. C. (2000) Calpastatin immunoreactivity in the monkey and human brain of control subjects and patients with Parkinson's disease. J. Comp. Neurol. 419: 175-192
92. Takeuchi N., Ito H., Namiki K. and Kamei A. (2001) Effect of calpain on hereditary cataractous rat, ICR/f. Biol. Pharm. Bull. 24: 1246-1251
93. Badalamente M. A. and Stracher A. (2000) Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. Muscle Nerve 23: 106-111
94. Tidball J. G. and Spencer M. J. (2002) Expression of calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J. Physiol. 545: 819-828
95. Bradsley R. G., Allcock S. M., Dawson J. M., Dumelow, N. W., Higgins J. A., Lasslett Y. V. et al. (1992) Effect of beta-agonists on expression of calpain and calpastatin activity in skeletal muscle. Biochemie 74: 267-273
96. Johari S., Maeda Y., Okamoto S. and Hashiguchi T. (1993) Comparison of calpain and calpastatin activities in skeletal muscle of broiler and layer chickens. Br. Poult Sci. 34: 819-24
97. Gil-Parrado S., Assfalg-Machleidt I., Fiorino F., Deluca D., Pfeiler D., Schaschke N. et al. (2003) Calpastatin exon 1B-derived peptide, a selective inhibitor of calpain: enhancing cell permeability by conjugation with penetrain. Biol. Chem. 384: 395-402
98. Ogrinc T., Dolenc I., Ritonja A. and Turk V. (1993) Purif ication of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney. FEBS Lett. 336: 555-559
99. Yamashita M. and Konagaya S. (1996) A novel cysteine protease inhibitor of the egg of chum salmon, containing a cysteine-rich thyroglobulin-like motif. J. Biol. Chem. 271: 1282-1284
100. Lenarčič B., Ritonja A., Strukelj B., Turk B. and Turk V. (1997) Equistatin, a new inhibitor of cysteine proteinases from Actinia equina, is structurally related to thyroglobulin type-1 domain. J. Biol. Chem. 272: 13899-13903
101. Lenarčič B., Krishan G., Borukhovich R., Ruck B., Turk V. and Moczydlowski E. (2000) Saxiphilin, a saxitonin-binding protein with two thyroglobulin type 1 domains, is an inhibitor of papain-like cysteine proteases. J. Biol. Chem. 275: 15572-15577
102. Lenarčič B. and Bevec T. (1998) Thyropins - new structurally related proteinase inhibitors. Biol. Chem. 379: 105-111
103. Gunčar G., Pungerčič G., Klemenčič I., Turk V. and Turk D. (1999) Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J. 18: 793-803
104. Bevec T., Stoka V., Pungerčič G., Dolenc I. and Turk V. (1996). Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J. Exp. Med. 183: 1331-1338
105. Katunuma N., Kakegawa H., Matsunaga Y. and Saibara T. (1994) Immunological significances of invariant chain from the aspect of its structural homology with the cystatin family. FEBS Lett. 349: 265-269
106. Galeča K., Pain R., Jongsma M. A., Turk V. and Lenarčič B. (2003) Structural characterization of thyroglobulin type-1 domains of equistatin. FEBS Lett. 539: 120-124
107. Bunn R. C. and Fowlkes J. L. (2003) Insulin-like growth factor binding protein proteolysis. TIEM 14: 176-181
108. Crook N. E., Clem R. J. and Miller L. K. (1993) An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 67: 2168-2174
109. Deveraux Q. L. and Reed J. C. (1999) IAP family proteins - suppressors of apoptosis. Genes Dev. 13: 239-252
110. Salvesen G. S. and Duckett C. S. (2002) IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3: 401-410
111. Deveraux Q. L., Takahashi R., Salvesen G. S. and Reed J. C. (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388: 300-304
112. Roy N., Deveraux Q. L., Takahashi R., Salvesen G. S. and Reed J. C. (1997) The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16: 6914-6925
113. Reed J. C. and Bischoff J. R. (2000) BIRinging chromosomes through cell division-and survivin' the experience. Cell 102: 545-548
114. Maier J. K. X., Lahoua Z., Gendron N. H., Fetni R., Johnston A., Davoodi J. et al. (2002) The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J. Neurosci. 22: 2035-2043
115. Shiozaki E. N., Chai J., Rigotti D. J., Riedl S. J., Li P., Srinivasula S. M. et al. (2003) Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11: 519-527
116. Chai J., Shiozaki E., Srinivasula S. M., Wu Q., Datta P., Alnemri E. S. et al. (2001) Structural basis of caspase-7 inhibition by XIAP. Cell 104: 769-780
117. Huang Y., Park Y. C., Rich R. L., Segal D., Myszka D. G. and Wu H. (2001) Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104: 781-790
118. Riedl S. J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., Fesik S. W. et al. (2001). Structural basis for the inhibition of caspase-3 by XIAP. Cell 104: 791-800
119. Du C., Fang M., Li Y., Li L. and Wang X. (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42
120. Wu G., Chai J., Suber T. L., Wu J.-W., Du C., Wang X. et al. (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature 408: 1008-1012
121. Sanna M. G., Correia J., Luo Y., Chuang B., Paulson L. M., Nguyen B. et al. (2002). ILPIP, a novel anti-apoptotic protein that enhances XIAP-mediated activation of JNK1 and protection against apoptosis. J. Biol. Chem. 277: 30454-30462
122. Silke J., Hawkins C. J., Ekert P. G., Chew J., Day C. L., Pakusch M. et al. (2002) The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. J. Cell Biol. 157: 115-124
123. Novelli G., Semprini S., Capon F. and Dallapiccola B. (1997) A possible role of NAIP gene deletions in sex-related spinal muscular atrophy phenotype variation. Neurogenet. 1: 29-30
124. Scharf J. M., Endrizzi M. G., Wetter A., Huang S., Thompson T. G., Zerres K. et al. (1998) Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics. Nat. Genet. 20: 83-86
125. Dierlamm J., Baens M., Wlodarska I., Stefanova-Ouzounova M. Hernandez J. M., Hossfeld D. K. et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene. MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93: 3601-3609
126. Vucic D., Stennicke H. R., Pisabarro M. T., Salvesen G. S. and Dixit V. M. (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 10: 1359-1366
127. Imoto I., Yang Z.-Q., Pimkhaokham A., Tsuda H., Shimada Y., Imamura M. et al. (2001) Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 61: 6629-6634
128. Tamm I., Kornblau S. M., Segall H., Krajewski, S., Welsh K., Kitada, S. et al. (2000) Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6: 1796-1803
129. Fong W. G., Liston P., Rajcan-Separovic E., St Jean M., Craig C. and Komeluk R. G. (2000) Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 70: 113-122
130. Holcik M., Thompson C. S., Yaraghi Z., Lefebvre C. A., MacKenzie A. E. and Korneluk R. G. (2000) The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury. Proc. Natl. Acad. Sci. USA 97: 2286-2290
131. Harlin H., Reffey S. B., Duckett C. S., Lindsten T. and Thompson C. B. (2001) Characterization of XIAP deficient mice. Mol. Cell. Biol. 21: 3604-3608
132. Uren A. G., Wong L., Pakusch M., Fowler K. J., Burrows F. J., Vaux D. L. et al. (2000) Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 10: 1319-1328
133. Clem R. J., Fechheimer M. and Miller L. K. (1991) Prevention of apoptosis by a baculovirus gene during infection of insect cells. Science 254: 1388-1390
134. Xu G., Cirilli M., Huang Y., Rich R. L., Myszka D. G. and Wu H. (2001) Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex. Nature 410: 494-497
135. Snipas S. J., Stennicke H. R., Riedl S., Potempa J., Travis J., Barrett A. J. et al. (2001) Inhibition of distant caspase homologues by natural caspase inhibitors. Biochem. J. 357: 575-580
136. Gent D., Sharp P., Morgan K. and Kalsheker N. (2003) Serpins: structure, function and molecular evolution. IJBCB 35: 1536-1547
137. Renatus M., Zhou Q., Stennicke H. R., Snipas S. J., Turk D., Bankston L. A. et al. (2000) Crystal structure of the apoptotic suppressor CrmA in its cleaved form. Structure 8: 789-797
138. Simonovic M., Gettins P. G. W. and Volz K. (2000) Crystal structure of viral serpin crmA provides insights into its mechanism of cysteine proteinase inhibition. Prot. Sci. 9: 1423-1427
139. Schick C., Brömme D., Bartuski A. J., Uemura Y., Schlechter N. M. and Silverman G. A. (1998) The reactive site loop of the serpin SCCA1 is essential for cysteine proteinase inhibition. Proc. Natl. Acad. Sci. USA 95: 13465-13470
140. Nathaniel R., MacNeill A. L., Wang Y. X., Turner P. C. and Moyer R. W. (2004) Cowpox virus CrmA, Myxoma virus SERP2 and baculovirus P35 are not functionally interchangeable caspase inhibitors in poxvirus infections. J. Gen. Virol. 85: 1267-1278
141. Messud-Petit F., Gelfi J., Delverdier M., Amardeilh M.-F., Py R., Sutter G. et al. (1998) Serp2, an inhibitor of the interleukin-1β-converting enzyme, is critical in the pathobiology of myxoma virus. J. Virol. 72: 7830-7839
142. Li X-K., Kosuga M., Tokieda K., Kanaji A., Fukuhara Y., Hashimoto M. et al. (2002) Prolongation of transgene expression by coexpression of cytokine response modifier a in rodent liver after adenoviral gene transfer. Mol. Ther. 5: 262-268.
143. Fujino M., Li X.-K., Suda T., Hashimoto M., Okabe K., Yaginuma H. et al. (2001) In vitro prevention of cell-mediated xeno-graft rejection via the Fas/FasL-pathway in CrmA-transducted porcine kidney cells. Xenotransplantation 8: 115-124
144. Fox T., de Miguel E., Mort J. S. and Storer A. C. (1992) Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry 31: 12571-12576
145. Wiederanders B. (2003) Structure-function relationships in class CA1 cysteine peptidase propeptides. Acta Biochim. Pol. 50: 691-713
146. Yamamoto Y., Kurata M., Watabe S., Murakami R. and Takahashi S. Y. (2002) Novel cysteine proteinase inhibitors homologous to the proregions of cysteine proteinases. Curr. Prot. Pept. Sci. 3: 231-238
147. Denizot F., Brunet J. F., Roustan P., Harper K., Suzan M., Luciani M. F. et al. (1989) Novel structures CTLA-2 alpha and CTLA-2 beta expressed in mouse activated T cells and mast cells and homologous to cysteine proteinase proregions. Eur. J. Immunol. 19: 631-635
148. Delaria K., Fiorentino L., Wallace L., Tamburini P., Brownell E. and Muller D. (1994) Inhibition of cathepsin L-like cysteine proteases by cytotoxic T-lymphocyle antigen-2β. J. Biol. Chem. 269: 25172-25177
149. Yamamolo Y., Watabe S., Kageyama T. and Takahashi S. Y. (1999) A novel inhibitor protein for Bombyx cysteine proteinase is homologous to propeptide regions of cysteine proteinases. FEBS Lett. 448: 257-260
150. von der Helm K., Korant B. D. and Cheronis J. C., eds (2000) Proteases as Targets For Therapy, Handb. Exp. Pharm. vol. 140, Springer Berlin
151. Schuler T. H., Poppy G. M., Kerry B. R. and Denholm I. (1998) Insect-resistant transgenic plants. Trends Biotech. 16: 168-175